Allena Pharmaceuticals Inc (NASDAQ:ALNA) – Stock analysts at Jefferies Group dropped their FY2017 earnings estimates for Allena Pharmaceuticals in a research note issued on Tuesday. Jefferies Group analyst M. Andrews now expects that the company will post earnings per share of ($3.34) for the year, down from their prior forecast of ($1.23). Jefferies Group currently has a “Buy” rating and a $22.00 target price on the stock. Jefferies Group also issued estimates for Allena Pharmaceuticals’ Q4 2017 earnings at ($0.25) EPS, FY2018 earnings at ($1.49) EPS, FY2019 earnings at ($1.65) EPS, FY2020 earnings at ($2.14) EPS, FY2021 earnings at ($1.42) EPS and FY2022 earnings at ($1.31) EPS.
Allena Pharmaceuticals (NASDAQ:ALNA) last issued its quarterly earnings results on Thursday, December 14th. The company reported ($3.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($3.11).
Allena Pharmaceuticals (ALNA) opened at $6.38 on Thursday. Allena Pharmaceuticals has a 52 week low of $6.15 and a 52 week high of $15.40. The company has a debt-to-equity ratio of -0.09, a quick ratio of 4.83 and a current ratio of 4.83.
Several hedge funds have recently made changes to their positions in the stock. Frazier Management LLC bought a new stake in shares of Allena Pharmaceuticals during the 4th quarter worth about $33,504,000. Sphera Funds Management LTD. bought a new stake in shares of Allena Pharmaceuticals during the 4th quarter worth about $3,270,000. Perceptive Advisors LLC bought a new stake in shares of Allena Pharmaceuticals during the 4th quarter worth about $2,515,000. BlackRock Inc. bought a new stake in shares of Allena Pharmaceuticals during the 4th quarter worth about $2,281,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of Allena Pharmaceuticals during the 4th quarter worth about $499,000. 0.07% of the stock is owned by institutional investors and hedge funds.
WARNING: This report was first published by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/02/15/jefferies-group-weighs-in-on-allena-pharmaceuticals-incs-fy2017-earnings-alna.html.
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones.
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.